Notable Labs LtdOTC Pink - Current Information:NTBLQ
- LAST PRICE0.1850
- TODAY'S CHANGE (%)0.0250 (15.6250%)
- Bid / Lots0.1700/ 50
- Ask / Lots0.2600/ 25
- Open / Previous Close0.1600 / 0.1600
- Day Range
- 52 Week Range
- Volume47,785
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NTBLQ |
|---|---|---|
| 09:41 ET | 114 | 0.16 |
| 09:48 ET | 100 | 0.16 |
| 09:52 ET | 347 | 0.16 |
| 10:19 ET | 625 | 0.161 |
| 10:30 ET | 100 | 0.163 |
| 10:32 ET | 5000 | 0.16 |
| 10:42 ET | 1430 | 0.16 |
| 10:51 ET | 162 | 0.16 |
| 11:00 ET | 5000 | 0.17 |
| 11:15 ET | 3044 | 0.171 |
| 11:20 ET | 925 | 0.171 |
| 11:22 ET | 100 | 0.171 |
| 11:49 ET | 625 | 0.171 |
| 11:58 ET | 200 | 0.171 |
| 12:14 ET | 195 | 0.171 |
| 01:14 ET | 3000 | 0.1805 |
| 01:37 ET | 600 | 0.176 |
| 02:29 ET | 625 | 0.176 |
| 02:33 ET | 2500 | 0.176 |
| 02:42 ET | 500 | 0.176 |
| 03:23 ET | 2500 | 0.176 |
| 03:25 ET | 4000 | 0.176 |
| 03:36 ET | 5000 | 0.176 |
| 03:39 ET | 5520 | 0.181 |
| 03:52 ET | 5000 | 0.185 |
Oct 23, 2024
*DJ News On Notable Labs Ltd. (NTBL) Now Under NTBLQ, from 5:08PM ET on Wednesday Oct 23, 2024 by Dow Jones
5:08PM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 15, 2024
DJ Notable Labs Files for Chapter 7 Bankruptcy, from 6:50AM ET on Tuesday Oct 15, 2024 by Dow Jones
6:50AM ET on Tuesday Oct 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Notable Labs Ltd | 1.5M | -0.1x | --- |
Peak Bio Inc | 1.6M | -0.3x | --- |
Herborium Group Inc | 1.1M | 0.0x | --- |
Regen BioPharma Inc | 2.1M | -2.1x | --- |
Cyclacel Pharmaceuticals Inc | 1.3M | 0.0x | --- |
Fresh2 Group Ltd | 5.2M | 0.0x | --- |
Company Information
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Contact Information
- Headquarters
- 320 Hatch DriveFOSTER CITY, CA, United States 94404
- Phone
- 415-851-2410
- Fax
- ---
Executives
- Senior Vice President - Research and Operations
- Eyal Breitbart
- Senior Vice President - Business Operations
- Erez Feige
- Senior Vice President - Clinical Development
- Tami Rachmilewitz
- Senior Vice President - Drug Development & Regulatory Affairs
- Naamit Sher
- Chief Medical Officer
- Glenn Michelson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5M |
|---|---|
Revenue (TTM) | $313.0K |
Shares Outstanding | 9.7M |
Notable Labs Ltd does not pay a dividend. | |
Beta | 0.97 |
EPS | $-2.47 |
Book Value | $1.68 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,493.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
